Clinical trial · Interventional
Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
NCT05977803CI-TRIAL-00106927ACROPrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to determine whether the use of the CEST sequence would have diagnostic performance equivalent to the reference method of T2\* infusion with contrast injection in the diagnosis of radionecrosis of lung cancer brain metastases.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | — | UNRESOLVED | — |
| Pulmonary Cancer | — | UNRESOLVED | — |
| Radionecrosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI with CEST sequence, IVIM and ASL sequence | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Radiation therapy
- description
- Patient treated for metastatic cerebral lung cancer who has been treated with external beam radiotherapy such as in toto brain irradiation or stereotactic radiosurgery followed in the thoracic oncology department of Bichat Hospital.
- interventionNames
- Radiation: MRI with CEST sequence, IVIM and ASL sequence
Primary outcomes (1)
- measure
- Visually significant hyperperfusion on normalized cerebral blood flow mapping generated from T2* infusion data with injection, confirmed by quantitative measurement of a ratio > 2.5 between tumor DSC and contralateral white matter.
- timeFrame
- 24 months
- description
- Diagnostic performance of the CEST sequence in the diagnosis of radionecrosis on irradiated metastases of primary lung cancer compared to injected T2\* infusion sequence
Secondary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients \> 18 years of age * Histologically proven primary lung cancer * Histologically proven or not brain metastases * Irradiated metastases * Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy * Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI * Patients affiliated to a social security scheme Exclusion Criteria: * Opposition to the study * Contraindication to MRI * Refusal of imaging by the patient * Patient with state medical aid (unless exemption from affiliation) * Severe cognitive impairment making informed consent impossible * Patients under guardianship or deprived of liberty
References
Publications (0)
Data not yet available
No reference posted for this study.